SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021 , the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common
- Industry veteran Garry Neil , MD, named Board Chair - Nawal Ouzren, CEO of Sensorion named to Board SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil , MD, has been appointed Chair of the
– Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC) – Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022 – Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response,
SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common
SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at
SAN DIEGO , Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common
- Data selected for late-breaker oral presentation on December 14 - Novel mechanism of action evaluated in moderate-to-severe atopic dermatitis (AD) - Significant unmet need exists for a safe, once-daily, oral therapy in AD SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC) - Topline data from ELEVATE UC 12 and UC 52 trials on track for Q1 2022 - Due to the high number of participants currently in screening queue, screening to continue for an additional three
Paul D. Streck , M.D., Appointed as Senior Vice President, Clinical Development and Chief Medical Officer, Bringing Successful Development and Launch Experience Across Multiple Therapeutic Indications SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2020-- Arena Pharmaceuticals, Inc.
SAN DIEGO , Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Tuesday,